News Gabather AB

Equities

GABA

SE0010869552

Market Closed - Nasdaq Stockholm Other stock markets 16:13:21 07/06/2024 BST			5-day change	1st Jan Change
1.815 ^SEK	-0.27%		+9.67%	+28.72%

05-30	Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-10	Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002	04-10	AQ
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	04-10	CI
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	03-18	MT
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders	03-18	AQ
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders	03-18	CI
Gabather reports initial positive results from the EEG/fMRI target engagement study	03-07	AQ
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study	03-07	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29	CI
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study	12-22	AQ
Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)	12-14	AQ
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002	12-14	CI
Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG	12-11	AQ
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-27	CI
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12/10/23	AQ
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12/10/23	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957	13/04/23	AQ
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application	13/04/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Gabather AB

Equities

GABA

SE0010869552

Summary

Filters